Quattro Financial Advisors LLC Increases Position in Pfizer Inc. (NYSE:PFE)

Quattro Financial Advisors LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 327,486.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 95,000 shares of the biopharmaceutical company’s stock after buying an additional 94,971 shares during the quarter. Pfizer comprises approximately 0.7% of Quattro Financial Advisors LLC’s investment portfolio, making the stock its 29th biggest holding. Quattro Financial Advisors LLC’s holdings in Pfizer were worth $2,636,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. VisionPoint Advisory Group LLC boosted its holdings in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the last quarter. GoalVest Advisory LLC boosted its holdings in Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares during the last quarter. Creekmur Asset Management LLC purchased a new stake in Pfizer in the fourth quarter valued at $32,000. Trivant Custom Portfolio Group LLC boosted its holdings in Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 600 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners purchased a new stake in Pfizer in the fourth quarter valued at $36,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

PFE stock traded down $0.39 during mid-day trading on Tuesday, reaching $27.83. The company’s stock had a trading volume of 21,710,519 shares, compared to its average volume of 40,642,027. The stock has a market cap of $157.70 billion, a PE ratio of -464.76, a P/E/G ratio of 1.10 and a beta of 0.69. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $37.80. The company’s 50 day moving average is $27.93 and its two-hundred day moving average is $27.70.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The business had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business’s revenue was down 19.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.23 EPS. Equities research analysts expect that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be given a $0.42 dividend. The ex-dividend date of this dividend is Thursday, July 25th. This represents a $1.68 annualized dividend and a yield of 6.04%. Pfizer’s dividend payout ratio is presently -2,799.53%.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Wednesday, June 26th. Morgan Stanley increased their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, BMO Capital Markets reissued an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Nine research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $35.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.